Meredith Buxton Discusses the I-SPY 2 Trial
Meredith Buxton, PhD, University of California San Francisco, discusses the I-SPY 2 trial, for which she is the executive director.
Meredith Buxton, PhD, University of California San Francisco, discusses the I-SPY 2 trial, for which she is the executive director.
The goal of I-SPY 2 is to test new agents, like immunotherapies, and ultimately get them to patients sooner. While it is currently only being used in the breast cancer domain, Buxton noted that hopefully other cancer types will also join in the trial.
Workflow, Educational Tools Improve Use of Silicone Film to Prevent Radiation Dermatitis
April 25th 2024Tools to educate oncology nurses and patients on the use of Mepitel film to prevent radiation dermatitis has improved the workflow around its introduction to patients with breast cancer, as well as its application and maintenance.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
